Zenas Bio Reports Phase 3 Obexelimab Data With 93% 12-Month Flare-Free Rate
Zenas Bio said Phase 3 INDIGO data showed sustained clinical activity, reduced steroid toxicity and promising vaccine responses.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.